Home Crystal structure of 2-(4-(2-(4-(2-fluorophenyl)piperazin-1-yl)ethyl)benzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide, C26H26FN3O3S – a saccharin dervative
Article Open Access

Crystal structure of 2-(4-(2-(4-(2-fluorophenyl)piperazin-1-yl)ethyl)benzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide, C26H26FN3O3S – a saccharin dervative

  • Hong Chen EMAIL logo and Hui-Xia Jia
Published/Copyright: November 8, 2017
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 233 Issue 1

Abstract

C26H26F1N3O3S1, triclinic, P1̅ (no. 2), a = 7.0252(14) Å, b = 9.3017(19) Å, c = 19.388(4) Å, α = 97.80(3)°, β = 97.77(3)°, γ = 106.84(3)°, V = 1180.9(5) Å3, Z = 2, Rgt(F) = 0.0729, wRref(F2) = 0.1854, T = 296.15 K.

CCDC no.:: 1578933

The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Block, clear light yellow
Size:0.16 × 0.12 × 0.12 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:90.18 mm−1
Diffractometer, scan mode:Bruker P4, ω-scans
2θmax, completeness:25.3°, 98%
N(hkl)measured, N(hkl)unique, Rint:19521, 4252, 0.149
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 3291
N(param)refined:307
Programs:Bruker programs [1], SHELX [2], OLEX2 [3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
S11.12276(11)0.18097(7)0.92905(3)0.0463(2)
F1−0.0029(2)0.13890(19)0.24270(8)0.0577(4)
O11.3174(3)0.5703(2)0.88626(10)0.0589(5)
O21.2623(3)0.0968(2)0.93180(11)0.0710(6)
O30.9126(3)0.0962(2)0.90818(11)0.0687(6)
N10.0003(3)0.2318(2)0.38308(10)0.0345(5)
N20.2411(3)0.1984(2)0.50894(10)0.0357(5)
N31.1891(3)0.3122(2)0.87851(10)0.0410(5)
C1−0.1682(4)0.1746(3)0.25980(13)0.0389(6)
C2−0.3220(4)0.1643(3)0.20618(14)0.0505(7)
H2−0.31660.12940.15940.061*
C3−0.4855(4)0.2068(3)0.22270(15)0.0525(7)
H3−0.59240.20000.18710.063*
C4−0.4891(4)0.2593(3)0.29206(15)0.0491(7)
H4−0.59780.29020.30310.059*
C5−0.3335(4)0.2669(3)0.34581(13)0.0429(6)
H5−0.34030.30130.39250.051*
C6−0.1664(3)0.2237(2)0.33124(12)0.0353(5)
C70.0161(4)0.0815(2)0.39356(12)0.0390(6)
H7A0.00670.01940.34800.047*
H7B−0.09530.02980.41500.047*
C80.2145(4)0.0991(3)0.44063(12)0.0408(6)
H8A0.2189−0.00070.44860.049*
H8B0.32520.14170.41690.049*
C90.2222(4)0.3456(3)0.49653(13)0.0465(7)
H9A0.32990.39480.47290.056*
H9B0.23670.41110.54160.056*
C100.0206(4)0.3265(3)0.45172(13)0.0466(6)
H10A−0.08770.27880.47540.056*
H10B0.01060.42580.44520.056*
C110.4338(4)0.2146(3)0.55249(12)0.0429(6)
H11A0.54200.27060.53090.051*
H11B0.44670.11370.55340.051*
C120.4600(4)0.2967(3)0.62846(13)0.0466(6)
H12A0.46750.40250.62850.056*
H12B0.34330.24930.64850.056*
C130.6492(4)0.2908(3)0.67369(12)0.0396(6)
C140.6484(4)0.1641(3)0.70453(13)0.0446(6)
H140.52920.08300.69770.053*
C150.8211(4)0.1563(3)0.74506(13)0.0425(6)
H150.81660.07050.76530.051*
C161.0018(4)0.2753(3)0.75603(12)0.0389(6)
C171.0044(4)0.4013(3)0.72511(13)0.0472(6)
H171.12420.48160.73130.057*
C180.8300(4)0.4089(3)0.68496(13)0.0483(7)
H180.83450.49510.66510.058*
C191.1901(4)0.2701(3)0.80278(12)0.0453(6)
H19A1.20020.16770.79340.054*
H19B1.30830.33940.79090.054*
C201.2566(3)0.4619(3)0.91420(13)0.0411(6)
C211.2405(3)0.4644(3)0.98975(13)0.0408(6)
C221.2841(4)0.5915(3)1.04280(15)0.0520(7)
H221.33190.69001.03370.062*
C231.2536(4)0.5658(4)1.11023(15)0.0618(8)
H231.28310.64931.14670.074*
C241.1816(5)0.4221(4)1.12440(15)0.0647(8)
H241.16250.40991.17000.078*
C251.1367(4)0.2942(4)1.07184(14)0.0581(8)
H251.08710.19581.08090.070*
C261.1695(4)0.3201(3)1.00528(13)0.0430(6)

Source of material

The title compound was synthesized starting with saccharin N-(4-(methyl)phenethyl 4-methylbenzenesulfonate). To a solution of saccharin N-(4-(methyl)phenethyl 4-methylbenzenesulfonate) (100 mg, 0.21 mmol) in acetonitrile (CH3CN, 10 mL) was added 1-(2-fluorophenyl)piperazine (45.36 mg, 0.25 mmol) and potassium carbonate (173 mg, 1.26 mmol). The reaction mixture was stirred at reflux for 16 h. After cooling to ambient temperature, the reaction mixture was filtered through a Buchner funnel. After filtration the filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography using ethyl acetate/petroleum ether (1/4, v/v) as eluent to afford the title compound [4].

Experimental details

The hydrogen atoms were assigned with isotropic displacement factors Uiso(H) = 1.2Ueq (N and imidazol C), or Uiso(H) = 1.5Ueq (methyl C) and included in the final refinement by using geometrical restraints, with C—H = 0.93 Å (imidazol) or C—H = 0.96 Å (methyl), and N—H = 0.86 Å.

Discussion

The saccharin moiety has been identified as an important molecular component in various classes of 5HT1a antagonists [5], human leukocyte elastase (HLE) inhibitors [6], [7], [8], [9], [10], analgesics [11], human mast cell tryptase inhibitors [12], α1a adrenergic receptor antagonists [13] and aldehyde dehydrogenase inhibitors [14]. Moreover, compounds with arylpiperazine moieties have anti-proliferative properties [15, 16] . For these reasons, the efficient synthesis of arylpiperazine derivatives containing the saccharin moiety attract the interest of synthetic chemists. In this context, we report the synthesis of the title compound.

The molecule of the title compound consists of a 1,4-piperazine moitey, a benzo[b]thiophene moiety (saccharin), the ethyl bezyl moiety as well as a 2-fluorophenyl group (cf. the figure). The best planes of the piperazine moiety, the 2-fluorophenyl group and the central arene unit are not in the same plane. The whole molecule is in a twisty conformation. C7—N1—C6—C1 torsion angles between 1,4-piperazine ring and the 2-fluoro-benzene ring is −70°, which clearly deviate from planarity. The angle is 34° between the central arene ring and the benzo[b]thiophene. In the molecule, the N(1)—C(6), N(1)—C(7), N(1)—C(10), N(2)—C(8), N(2)—C(9), N(2)—N(11) bond lengths are found to be 1.413(3) Å, 1.472(3) Å, 1.458(3) Å, 1.464(3) Å, 1.461(3) Å and 1.452(3) Å, respectively, which are nearly equal to other typical single bonds. The bond lengths of C(20)—O(3) is found to be 1.206(4) Å, which is in accordance with a typical double bond. S(1)—O(2) and S(1)—O(3) are 1.421(2) and 1.429(9) Å, respectively, which is in accordance with the expectations [17]. The bond angles C6—N1—C7, C6—N1—C10, C10—N1—C7, C11—N2—C8, C11—N2—C9 and C9—N2—C8 are 113.86(18), 116.07(19), 109.36(18), 111.44(18)°, 112.20(19) and 109.01(18)°, respectively. Furthermore, the angles C20—N3—S1, C20—C3—C19, C19—N3—S1 are 115.06(17), 122.8(2), 121.97(17), respectively.

Acknowledgements

This work was supported by the Natural Science Foundation of China (No. 81401462), Henan Province Science and Technology Attack Plan Foundation (No. 162102310477), the Key Scientific Research Project of Higher Education of Henan Province (Nos. 16A350008, 17A150039 and 17B350001) and National Scientific Research Foundation of Luoyang Normal University (No. 2015-PYJJ-005).

References

Bruker: APEX2, SAINT and SADABS. Brucker AXS Inc., Madison, WI, USA (2009).Search in Google Scholar

Sheldrick, G. M.: A short history of SHELX. Acta. Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar

Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H.: OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Cryst. 42 (2009), 339–341.10.1107/S0021889808042726Search in Google Scholar

Chen, H.; Liang, X.; Xu, F.; Xu, B.-B.; He, X.-L.; Huang, B.-Y.; Yuan, M.: Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines. Molecules 9 (2014) 12048–12064.10.3390/molecules190812048Search in Google Scholar

Romero, A. G.; Darlington, W. H.; Piercey, M. F.; Lahti, R. A.: Synthesis of metabolically stable arylpiperazine 5-HT1A receptor agonists. Bioorg. Med. Chem. Lett. 9 (1992) 1703–1706.10.1016/S0960-894X(00)80460-6Search in Google Scholar

Martyn, D. C.; Moore, M. J.; Abell, A. D.: Succinimide and saccharinbased enzyme-activated inhibitors of serine proteases. Curr. Pharm. Des. 9 (1999) 405–415.Search in Google Scholar

Groutas, W. C.; Epp, J. B.; Venkataraman, R.; Kuang, K.; Truong, T. M.; McClenahan, J. J.; Prakash, O.: Design, synthesis, and in vitro inhibitory activity toward human leukocyte elastase, cathepsin G, and proteinase 3 of saccharin-derived sulfones and congeners. Bioorg. Med. Chem. 9 (1996) 1393–1400.10.1016/0968-0896(96)00133-2Search in Google Scholar

Hlasta, D. J.; Bell, M. R.; Boaz, N. W.; Court, J. J.; Desai, R. C.; Franke, C. A.; Mura, A. J.; Subramanyam, C.; Dunlap, R. P.: A benzisothiazolone class of potent, selective mechanism-based inhibitors of human leukocyte elastase. Bioorg. Med. Chem. Lett. 9 (1994) 1801–1806.10.1016/S0960-894X(01)80374-7Search in Google Scholar

Hlasta, D. J.; Bell, M. R.; Court, J. J.; Cundy, K. C.; Desai, R. C.; Ferguson, E. W.; Gordon, R. J.; Kumar, V.; Maycock, A. L.; Subramanyam, C.: The design of potent and stable benzisothiazolone inhibitors of human leukocyte elastase. Bioorg. Med. Chem. Lett. 9 (1995) 331–336.10.1016/0960-894X(95)00030-WSearch in Google Scholar

Hlasta, D. J.; Subramanyam, C.; Bell, M. R.; Carabateas, P. M.; Court, J. J.; Desai, R. C.; Drozd, M. L.; Eickhoff, W. M.; Ferguson, E. W.; Gordon, R. J.; Johnson, J. A.; Kumar, V.; Maycock, A. L.; Mueller, K. R.; Pagani, E. D.; Robinson, D. T.; Saindane, M. T.; Silver, P. J.; Subramanian, S.; Dunlap, R. P.; Franke, C. A.; Mura, A. J.; Rowlands, A. G.: Orally bioavailable benzisothiazolone inhibitors of human leukocyte elastase. J. Med. Chem. 9 (1995) 739–744.10.1021/jm00005a001Search in Google Scholar

Gonzalez-Martin, G.; Lyndon, C.; Sunkel, C.: Hepatic kinetics of SCP-1(N-[α-(1,2-benzisothiazol-3(2H)-ona-1,1-dioxide-2-yl)-acetyl]-p-aminophenol) compared with acetaminophen in isolated rat liver. Eur. J. Pharm. Biopharm. 9 (1998) 293–297.10.1016/S0939-6411(98)00045-9Search in Google Scholar

Combrink, K. D.; Gulgeze, H. B.; Meanwell, N. A.; Pearce, B. C.; Zulan, P.; Bissacci, G. S.; Roberts, D. G. M.; Stanley, P.; Seiler, S. M.: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase. J. Med. Chem. 9 (1998) 4854–4860.10.1021/jm9804580Search in Google Scholar PubMed

Patane, M. A.; Dipardo, R. M.; Price, R. P.; Chang, R. S. L.; Ransom, R. W.; OMalley, S. S.; De-Salvo, J.; Bock, M. G.: Selective α-1A adrenergic receptor antagonists. Effects of pharmacophore regio- and stereochemistry on potency and selectivity. Bioorg. Med. Chem. Lett. 9 (1998) 2495–2500.10.1016/S0960-894X(98)00451-XSearch in Google Scholar

Nagasawa, H. T.; Kawle, S. P.; Elberling, J. A.; DeMaster, E. G.; Fukuto, J. M.: Prodrugs of nitroxyl as potential aldehyde dehydrogenase inhibitors vis-a-vis vascular smooth muscle relaxants. J. Med. Chem. 9 (1995) 1865–1871.10.1021/jm00011a005Search in Google Scholar PubMed

Berardi, F.; Abate, C.; Ferorelli, S.; De Robertis, A. F.; Leopoldo, M.; Colabufo, N. A.; Niso, M.; Perrone, R.: Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as delta(8)-delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity. J. Med. Chem. 9 (2008) 7523–7531.10.1021/jm800965bSearch in Google Scholar PubMed

Liu, W.-H.; Chang, J.-X.; Liu, Y.; Luo, J.-W.; Zhang, J.-W.: Design, synthesis and activities of novel benzothiazole derivatives containing arylpiperazine. Acta Pharmaceutica Sinica 9 (2013) 1259–1265.Search in Google Scholar

Lu, N.; Chiang, H.-F.; Wei, R.-J.; Wen, Y.-S.; Liu, L.-K.: Molecular structures of 3-[(2,2,3,3-tetrafluoropropoxy)methyl]- and 3-[(2,2,3,3,3-pentafluoropropoxy)methyl]pyridinium saccharinates. Acta Crystallogr. C73 (2017) 593–599.10.1107/S2053229617009512Search in Google Scholar PubMed

Received: 2017-7-11
Accepted: 2017-10-10
Published Online: 2017-11-8
Published in Print: 2018-1-26

©2018 Hong Chen et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Articles in the same Issue

  1. Cover and Frontmatter
  2. Editorial 2018
  3. Crystal structure of dimethanol-bis{3-(((2-oxidonaphthalen-1-yl)methylene)amino)-2-oxo-2H-chromen-4-olato-κ3O,N:O′}dizinc(II), C42H30Zn2N2O10
  4. Crystal structure of aqua-bis{[2,6-dimethyl-N-(pyridin-2-ylmethylene)aniline-κ2N,N′]}zinc(II) triflate monohydrate [ZnC29H31N4O]CF3SO3⋅H2O
  5. Crystal structure of (E)-1-(4-{[(E)-4-Diethylamino-2-hydroxybenzene methylene]amino}phenyl)ethanone methoxy oxime, C20H27ClN3O3
  6. Crystal structure of (E)-1-(4-(((E)-4-(diethylamino)-2-hydroxybenzylidene)amino)phenyl)ethan-1-one oxime, C19H23N3O2
  7. Crystal structure of poly[(μ2-1,4-bis((2-ethyl-1H-benzo[d]imidazol-1-yl)methyl)benzene-κ2N:N′)-(μ2-4,4′-sulfonyldibenzoato-κ2O:O′)zinc(II)], C40H34N4O6SZn
  8. Crystal structure of catena-poly[diaqua(μ3-pyrazine-2,3-dicarboxylato-κ4O,N:O′:O′′)zinc(II)] 1.25 hydrate, C6H8.5N2O7.25Zn
  9. Crystal structure of fac-(acetylacetonato-κ2O,O′)tricarbonyl(tri-m-tolyl phosphane-κP)rhenium(I), C29H28O5PRe
  10. Crystal structure of bis(μ2-methanolato-κ2O:O)-bis(methanol-κ1O)-bis{3-((4-methoxy-2-oxidobenzylidene)amino)-2-oxo-2H-chromen-4-olato-κ3O,O′,N}dichromium(III), C38H36Cr2N2O14
  11. Crystal structure of poly[aqua-(μ3-pyridine-3,5-dicarboxylato-κ5O,O′:O′′,O′′′,N)zinc(II)], C7H7NO6Zn
  12. Crystal structure of bis((1-(((4-(((benzyloxy)imino)methyl)phenyl)imino)methyl)naphthalen-2-yl)oxy-κ2O,N)copper(II), C52H42CuN4O4
  13. Crystal structure of bis{5-(diethylamino)-2-(((2-oxo-2H-chromen-6-yl)imino)methyl)phenolato-κ2O,N}cobalt(II), C40H38CoN4O6
  14. Crystal structure of diaqua-bis(N,N-dimethylformamide-κ1O)-bis{3-((5-chloro-2-oxidobenzylidene)amino)-2-oxo-2H-chromen-4-olato-κ4N,O,O′:O′}dinickel(II), C38H34Ni2Cl2N4O12
  15. Crystal structure of tetrakis(methanol-κO)bis{3-((4-methoxy-2-oxidobenzylidene)amino)-2-oxo-2H-chromen-4-olato-κ3O,N,O′}bicobalt(II), C38H38Co2N2O14
  16. Crystal structure of (S)-tert-butyl-(1-hydroxypropan-2-yl)carbamate, C8H17NO3
  17. Crystal structure of 4-(4′-(pyridin-4-yl)-[1,1′-biphenyl]-4-yl)pyridin-1-ium catena-poly[{5-carboxy-4′-methyl-[1,1′-biphenyl]-3-carboxylato-κ2O,O′}-(μ2-4′-methyl-[1,1′-biphenyl]-3,5-dicarboxylato-κ4O,O′:O′′,O′′′)lead(II)], C52H40N2O9Pb
  18. Crystal structure of catena-poly[diaqua-(μ2-5-methylisophthalato-κ2O:O′)(μ2-1,4-bis((1H-1,2,4-triazol-1-yl)methyl)benzene-κ2N:N′)], NiC21H22O6N6
  19. Crystal structure of the salt tris(guanidinium) tris(tetrapropylammonium) bis(pyridine-2,4,6-tricarboxylate) – water (1/10), C55H126N14O22
  20. Crystal structure of 5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3,7,8-trimethoxy-4H-chromen-4-one, C19H18O8
  21. Crystal structure of poly{[μ2-1,1′-(sulfonylbis(4,1-phenylene))bis(2-methyl-1H-imidazole)-κ2N:N′][μ2-4,4′-oxydibenzoato-κ2O:O′]cobalt(II)} hemihydrate, C34H27N4O7.5SCo
  22. The crystal structure of 25,27-(2,2′-[(2-thioxo-1,3-dithiole-4,5-diyl)disulfanediyl]diethanolate)-26,28-dihydroxycalix[4]arene — dichloromethane (1/1), C36H32Cl2O4S5
  23. The crystal structure of 1,2-bis(3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)ethane, C16H12N6O2
  24. Crystal structure of 1-benzyl-3-((4-bromophenyl)amino)-4-(4-methoxyphenyl)-1H-pyrrole-2,5-dione, C24H19BrN2O3
  25. Crystal structure of bis(2-((allylcarbamothioyl)imino)-4-methylthiazol-3-ido-κ2N,S)palladium(II), C16H20N6PdS4
  26. Crystal structure of pyrimidine-2,5-dicarboxylic acid 1.5 hydrate, C12H14N4O11
  27. Crystal structure of trans-diaqua-bis(1H-pyrazole-3-carboxylato-κ2N,O)manganese(II), C8H10N4O6Mn
  28. Crystal structure of catena-(μ3-5-bromoisophthatato-κO,O′: O′′,O′′′′)-(1,2-bis(imidazol-1-yl)ethane-κN:N′)cobalt(II), C16H13CoN4O4Br
  29. Investigation of the compound La5Zn2−xPb1 + x (x = 0.20–0.32)
  30. Crystal structure of (OC-6-13)-diaqua-bis(3,5-di(pyridin-3-yl)-4H-1,2,4-triazol-4-amine-κ1N)-bis(dicyanamido-κ1N)zinc(II) tetrahydrate, ZnC28H32N18O6
  31. Crystal structure of Ga0.62(3)Sb0.38(3)Pd3
  32. Crystal structure of Ga0.47(1)Sb0.53(1)Pd2
  33. A derivative of the Corey lactone – crystal structure of (3aR,4S,5R,6aS)-4-(((tert-butyldimethylsilyl)oxy)methyl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl benzoate, C21H30O5Si
  34. A Corey lactone: crystal structure of (3aR,4R,5R,6aS)-5-benzoyloxy-4(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one, C15H16O5
  35. Hydrothermal synthesis and crystal structure of poly[aqua-(μ2-1,3-bis(4-pyridyl)propane-κ2N:N′)-(μ2-1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylato-κ2O:O′)manganese(II) hydrate, C22H20Cl6N2O6Mn
  36. Crystal structure of 2-acetylpyrrole S-methylthiosemicarbazonium hydroiodide, C8H13IN4S
  37. Crystal structure of [N,N-bis((pyrrol-2-yl)ethylidene)butane-1,4-diamine-κ4N,N′,N′′,N′′′]-nickel(II), C16H20N4Ni
  38. Crystal structure of poly[aqua-(μ5-2,5-dicarboxybenzoato-κ5O:O:O′:O′′:O′′′)sodium(I)], C9H7NaO7
  39. Crystal structure of bis(N′-((1H-pyrrol-2-yl)methylene)-1-methylthio-methanethiohydrazido-κ2S,N)nickel(II), C14H16N6NiS4
  40. Crystal structure of 1-(4-((benzo[d][1,3]dioxol-5-yloxy)methyl)phenethyl)-4-(3-chlorophenyl) piperazin-1-ium chloride, C26H28Cl2N2O3
  41. Crystal structure of 2-(4-(2-(4-(2-fluorophenyl)piperazin-1-yl)ethyl)benzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide, C26H26FN3O3S – a saccharin dervative
  42. Crystal structure of 3-(2-dimethylaminoethyl)-2,3-dihydro-2-thioxoquinazolin-4(1H)-one, C12H15N3OS
  43. Crystal structure of 3-(3-dimethylaminopropyl)-2,3-dihydro-2-thioxoquinazolin-4(1H)-one, C13H17N3OS
  44. The crystal structure of trans-tetraaqua-bis(p-tolylsulfinato-κO)calcium(II)), C14H22O8S2Ca
  45. The crystal structure of (E)-N′-(pyridin-2-ylmethylene)pyrazine-2-carbohydrazide, C11H9N5O
  46. Crystal structure of (E)-3-(pyren-1-yl)-1-(pyridin-4-yl)prop-2-en-1-one, C24H15NO
  47. Crystal structure of catena-poly[diaqua-(μ2-tartrato-κ4O,O′:O′′,O′′′)cobalt(II)], C4H8CoO8
  48. Crystal structure of 4-chloro-2-methyl-6-(4-(trifluoromethoxy)phenyl)pyrimidine, C12H8ClF3N2O
  49. Crystal structure of 1-(4-fluorophenyl)-N-(5-((triphenylstannyl)thio)thiophen-2-yl)methanimine, C27H20FN3S2Sn
  50. Crystal structure of methyl (Z)-2-(5-fluoro-2-oxoindolin-3-ylidene)hydrazine-1-carbodithioate, C10H8FN3OS2
  51. Crystal structure of tert-butyl (Z)-4-(2-(5-methoxy-3-(2-((methylthio)carbonothioyl)hydrazono)-2-oxoindolin-1-yl)ethyl)piperazine-1-carboxylate, C22H31N5O4S2
  52. The crystal structure of (E)-2-((2-(o-tolylcarbamothioyl)hydrazono)methyl)benzoic acid, C16H15N3O2S
  53. Crystal structure of 2-chloro-1,3-di-tert-pentyl-4,4-diphenyl-1,3,2λ3,4-diazaphosphasiletidine, C22H32ClN2PSi
  54. Crystal structure of tetramethyl 5,5′-(buta-1,3-diyne-1,4-diyl)diisophthalate, C24H18O8
  55. Crystal structural of 2-amino-4-(4-methoxyphenyl)-3-cyano-7,7-dimethyl-5-oxo-4H-5,6,7,8-tetrahydrobenzo[b]pyran, C19H20N2O3
  56. Crystal structure of 1,3,5-tris((trimethylsilyl)methyl)-1,3,5-triazinane-2,4,6-trione, C15H33N3O3Si3
  57. The crystal structure of bis(2-benzoyl-5-hydroxylphenolato-κ2O,O′)copper(II), C26H18CuO6
  58. Crystal structure of 2,6-bis(3-(pyrazin-2-yl)-1H-1,2,4-triazol-5-yl)pyridine – 1-ethyl-3-methyl-1H-imidazol-3-ium bromide (1/1), C23H22N13Br
  59. The crystal structure of (E)-N-benzyl-N′-benzylidene-4-methylbenzenesulfonohydrazide, C21H20N2O2S
  60. Crystal structure of ethyl (E)-5-((2-(3-hydroxybenzoyl)hydrazono)methyl)-3,4-dimethyl-1H-pyrrole-2-carboxylate – water – ethanol (1/1/1), C19H27N3O6
  61. The crystal structure of (E)-4-(3-ethoxy-2-hydroxybenzylideneamino)benzoic acid, C16H15NO4
  62. Crystal structure of (μ2-N,N′-bis((pyridin-4-yl)methyl)ethanediamide-κ2N:N′)-tetrakis(diethylcarbamodithioato-κ2S,S′)dizinc(II), C34H54N8O2S8Zn2
https://doi.org/10.1515/ncrs-2017-0197
Creative Commons
BY-NC-ND 4.0

Articles in the same Issue

  1. Cover and Frontmatter
  2. Editorial 2018
  3. Crystal structure of dimethanol-bis{3-(((2-oxidonaphthalen-1-yl)methylene)amino)-2-oxo-2H-chromen-4-olato-κ3O,N:O′}dizinc(II), C42H30Zn2N2O10
  4. Crystal structure of aqua-bis{[2,6-dimethyl-N-(pyridin-2-ylmethylene)aniline-κ2N,N′]}zinc(II) triflate monohydrate [ZnC29H31N4O]CF3SO3⋅H2O
  5. Crystal structure of (E)-1-(4-{[(E)-4-Diethylamino-2-hydroxybenzene methylene]amino}phenyl)ethanone methoxy oxime, C20H27ClN3O3
  6. Crystal structure of (E)-1-(4-(((E)-4-(diethylamino)-2-hydroxybenzylidene)amino)phenyl)ethan-1-one oxime, C19H23N3O2
  7. Crystal structure of poly[(μ2-1,4-bis((2-ethyl-1H-benzo[d]imidazol-1-yl)methyl)benzene-κ2N:N′)-(μ2-4,4′-sulfonyldibenzoato-κ2O:O′)zinc(II)], C40H34N4O6SZn
  8. Crystal structure of catena-poly[diaqua(μ3-pyrazine-2,3-dicarboxylato-κ4O,N:O′:O′′)zinc(II)] 1.25 hydrate, C6H8.5N2O7.25Zn
  9. Crystal structure of fac-(acetylacetonato-κ2O,O′)tricarbonyl(tri-m-tolyl phosphane-κP)rhenium(I), C29H28O5PRe
  10. Crystal structure of bis(μ2-methanolato-κ2O:O)-bis(methanol-κ1O)-bis{3-((4-methoxy-2-oxidobenzylidene)amino)-2-oxo-2H-chromen-4-olato-κ3O,O′,N}dichromium(III), C38H36Cr2N2O14
  11. Crystal structure of poly[aqua-(μ3-pyridine-3,5-dicarboxylato-κ5O,O′:O′′,O′′′,N)zinc(II)], C7H7NO6Zn
  12. Crystal structure of bis((1-(((4-(((benzyloxy)imino)methyl)phenyl)imino)methyl)naphthalen-2-yl)oxy-κ2O,N)copper(II), C52H42CuN4O4
  13. Crystal structure of bis{5-(diethylamino)-2-(((2-oxo-2H-chromen-6-yl)imino)methyl)phenolato-κ2O,N}cobalt(II), C40H38CoN4O6
  14. Crystal structure of diaqua-bis(N,N-dimethylformamide-κ1O)-bis{3-((5-chloro-2-oxidobenzylidene)amino)-2-oxo-2H-chromen-4-olato-κ4N,O,O′:O′}dinickel(II), C38H34Ni2Cl2N4O12
  15. Crystal structure of tetrakis(methanol-κO)bis{3-((4-methoxy-2-oxidobenzylidene)amino)-2-oxo-2H-chromen-4-olato-κ3O,N,O′}bicobalt(II), C38H38Co2N2O14
  16. Crystal structure of (S)-tert-butyl-(1-hydroxypropan-2-yl)carbamate, C8H17NO3
  17. Crystal structure of 4-(4′-(pyridin-4-yl)-[1,1′-biphenyl]-4-yl)pyridin-1-ium catena-poly[{5-carboxy-4′-methyl-[1,1′-biphenyl]-3-carboxylato-κ2O,O′}-(μ2-4′-methyl-[1,1′-biphenyl]-3,5-dicarboxylato-κ4O,O′:O′′,O′′′)lead(II)], C52H40N2O9Pb
  18. Crystal structure of catena-poly[diaqua-(μ2-5-methylisophthalato-κ2O:O′)(μ2-1,4-bis((1H-1,2,4-triazol-1-yl)methyl)benzene-κ2N:N′)], NiC21H22O6N6
  19. Crystal structure of the salt tris(guanidinium) tris(tetrapropylammonium) bis(pyridine-2,4,6-tricarboxylate) – water (1/10), C55H126N14O22
  20. Crystal structure of 5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3,7,8-trimethoxy-4H-chromen-4-one, C19H18O8
  21. Crystal structure of poly{[μ2-1,1′-(sulfonylbis(4,1-phenylene))bis(2-methyl-1H-imidazole)-κ2N:N′][μ2-4,4′-oxydibenzoato-κ2O:O′]cobalt(II)} hemihydrate, C34H27N4O7.5SCo
  22. The crystal structure of 25,27-(2,2′-[(2-thioxo-1,3-dithiole-4,5-diyl)disulfanediyl]diethanolate)-26,28-dihydroxycalix[4]arene — dichloromethane (1/1), C36H32Cl2O4S5
  23. The crystal structure of 1,2-bis(3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)ethane, C16H12N6O2
  24. Crystal structure of 1-benzyl-3-((4-bromophenyl)amino)-4-(4-methoxyphenyl)-1H-pyrrole-2,5-dione, C24H19BrN2O3
  25. Crystal structure of bis(2-((allylcarbamothioyl)imino)-4-methylthiazol-3-ido-κ2N,S)palladium(II), C16H20N6PdS4
  26. Crystal structure of pyrimidine-2,5-dicarboxylic acid 1.5 hydrate, C12H14N4O11
  27. Crystal structure of trans-diaqua-bis(1H-pyrazole-3-carboxylato-κ2N,O)manganese(II), C8H10N4O6Mn
  28. Crystal structure of catena-(μ3-5-bromoisophthatato-κO,O′: O′′,O′′′′)-(1,2-bis(imidazol-1-yl)ethane-κN:N′)cobalt(II), C16H13CoN4O4Br
  29. Investigation of the compound La5Zn2−xPb1 + x (x = 0.20–0.32)
  30. Crystal structure of (OC-6-13)-diaqua-bis(3,5-di(pyridin-3-yl)-4H-1,2,4-triazol-4-amine-κ1N)-bis(dicyanamido-κ1N)zinc(II) tetrahydrate, ZnC28H32N18O6
  31. Crystal structure of Ga0.62(3)Sb0.38(3)Pd3
  32. Crystal structure of Ga0.47(1)Sb0.53(1)Pd2
  33. A derivative of the Corey lactone – crystal structure of (3aR,4S,5R,6aS)-4-(((tert-butyldimethylsilyl)oxy)methyl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl benzoate, C21H30O5Si
  34. A Corey lactone: crystal structure of (3aR,4R,5R,6aS)-5-benzoyloxy-4(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one, C15H16O5
  35. Hydrothermal synthesis and crystal structure of poly[aqua-(μ2-1,3-bis(4-pyridyl)propane-κ2N:N′)-(μ2-1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylato-κ2O:O′)manganese(II) hydrate, C22H20Cl6N2O6Mn
  36. Crystal structure of 2-acetylpyrrole S-methylthiosemicarbazonium hydroiodide, C8H13IN4S
  37. Crystal structure of [N,N-bis((pyrrol-2-yl)ethylidene)butane-1,4-diamine-κ4N,N′,N′′,N′′′]-nickel(II), C16H20N4Ni
  38. Crystal structure of poly[aqua-(μ5-2,5-dicarboxybenzoato-κ5O:O:O′:O′′:O′′′)sodium(I)], C9H7NaO7
  39. Crystal structure of bis(N′-((1H-pyrrol-2-yl)methylene)-1-methylthio-methanethiohydrazido-κ2S,N)nickel(II), C14H16N6NiS4
  40. Crystal structure of 1-(4-((benzo[d][1,3]dioxol-5-yloxy)methyl)phenethyl)-4-(3-chlorophenyl) piperazin-1-ium chloride, C26H28Cl2N2O3
  41. Crystal structure of 2-(4-(2-(4-(2-fluorophenyl)piperazin-1-yl)ethyl)benzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide, C26H26FN3O3S – a saccharin dervative
  42. Crystal structure of 3-(2-dimethylaminoethyl)-2,3-dihydro-2-thioxoquinazolin-4(1H)-one, C12H15N3OS
  43. Crystal structure of 3-(3-dimethylaminopropyl)-2,3-dihydro-2-thioxoquinazolin-4(1H)-one, C13H17N3OS
  44. The crystal structure of trans-tetraaqua-bis(p-tolylsulfinato-κO)calcium(II)), C14H22O8S2Ca
  45. The crystal structure of (E)-N′-(pyridin-2-ylmethylene)pyrazine-2-carbohydrazide, C11H9N5O
  46. Crystal structure of (E)-3-(pyren-1-yl)-1-(pyridin-4-yl)prop-2-en-1-one, C24H15NO
  47. Crystal structure of catena-poly[diaqua-(μ2-tartrato-κ4O,O′:O′′,O′′′)cobalt(II)], C4H8CoO8
  48. Crystal structure of 4-chloro-2-methyl-6-(4-(trifluoromethoxy)phenyl)pyrimidine, C12H8ClF3N2O
  49. Crystal structure of 1-(4-fluorophenyl)-N-(5-((triphenylstannyl)thio)thiophen-2-yl)methanimine, C27H20FN3S2Sn
  50. Crystal structure of methyl (Z)-2-(5-fluoro-2-oxoindolin-3-ylidene)hydrazine-1-carbodithioate, C10H8FN3OS2
  51. Crystal structure of tert-butyl (Z)-4-(2-(5-methoxy-3-(2-((methylthio)carbonothioyl)hydrazono)-2-oxoindolin-1-yl)ethyl)piperazine-1-carboxylate, C22H31N5O4S2
  52. The crystal structure of (E)-2-((2-(o-tolylcarbamothioyl)hydrazono)methyl)benzoic acid, C16H15N3O2S
  53. Crystal structure of 2-chloro-1,3-di-tert-pentyl-4,4-diphenyl-1,3,2λ3,4-diazaphosphasiletidine, C22H32ClN2PSi
  54. Crystal structure of tetramethyl 5,5′-(buta-1,3-diyne-1,4-diyl)diisophthalate, C24H18O8
  55. Crystal structural of 2-amino-4-(4-methoxyphenyl)-3-cyano-7,7-dimethyl-5-oxo-4H-5,6,7,8-tetrahydrobenzo[b]pyran, C19H20N2O3
  56. Crystal structure of 1,3,5-tris((trimethylsilyl)methyl)-1,3,5-triazinane-2,4,6-trione, C15H33N3O3Si3
  57. The crystal structure of bis(2-benzoyl-5-hydroxylphenolato-κ2O,O′)copper(II), C26H18CuO6
  58. Crystal structure of 2,6-bis(3-(pyrazin-2-yl)-1H-1,2,4-triazol-5-yl)pyridine – 1-ethyl-3-methyl-1H-imidazol-3-ium bromide (1/1), C23H22N13Br
  59. The crystal structure of (E)-N-benzyl-N′-benzylidene-4-methylbenzenesulfonohydrazide, C21H20N2O2S
  60. Crystal structure of ethyl (E)-5-((2-(3-hydroxybenzoyl)hydrazono)methyl)-3,4-dimethyl-1H-pyrrole-2-carboxylate – water – ethanol (1/1/1), C19H27N3O6
  61. The crystal structure of (E)-4-(3-ethoxy-2-hydroxybenzylideneamino)benzoic acid, C16H15NO4
  62. Crystal structure of (μ2-N,N′-bis((pyridin-4-yl)methyl)ethanediamide-κ2N:N′)-tetrakis(diethylcarbamodithioato-κ2S,S′)dizinc(II), C34H54N8O2S8Zn2
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 21.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2017-0197/html
Scroll to top button